Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Gigantol: a principal bioactive constituent of Dendrobium species-multi-target mechanisms, network pharmacology, and therapeutic perspectives.

  • 2026-01
  • Journal of ethnopharmacology 355
    • Sha Shi
    • Chengkai Zhu
    • Jiaqi Xu
    • Qi Sui
    • Shanhao Zhu
    • Jingnan Zhang
    • Peng Chen
    • Guang Liang
    • Yi Zhang

Study Design

Type
Review
Methods
extensive literature search using PubMed and CNKI databases until June 2025

Ethnopharmacological relevance

Gigantol, a naturally occurring bibenzyl compound isolated mainly from Dendrobium species, is traditionally used in Chinese and Southeast Asian medicine to nourish Yin, reduce internal heat, and treat inflammation-related diseases. Its broad pharmacological activities support its traditional applications and highlight its potential as a therapeutic agent.

Aim of the study

This review compiles existing evidence regarding the phytochemistry, pharmacological effects, pharmacokinetics, and molecular mechanisms of gigantol, while highlighting critical research gaps and future development directions.

Materials and methods

An extensive literature search was conducted using the PubMed and China National Knowledge Infrastructure (CNKI) databases until June 2025. Data on gigantol extraction, pharmacological activities, in vitro and in vivo studies, molecular docking, network pharmacology, and pharmacokinetics were collected and analyzed.

Results

Gigantol exhibits polypharmacological properties, including anticancer, antidiabetic, anti-inflammatory, and antioxidant activities. It modulates signaling pathways such as Phosphoinositide 3-kinase/Protein Kinase B (PI3K/Akt), Wingless/Integrated-1/β-catenin (Wnt/β-catenin), Nuclear Factor kappa-B (NF-κB), and Solute Carrier Family 7 Member 11-Glutathione Peroxidase 4 (SLC7A11-GPX4). Key targets identified include Prostaglandin-Endoperoxide Synthase 2 (PTGS2/COX-2), Estrogen Receptor 1 (ESR1), and Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1). Pharmacokinetic studies have shown rapid absorption, liver accumulation, phase II metabolism, and low toxicity. However, limited oral bioavailability and translational data remain significant challenges.

Conclusions

Gigantol holds promise as a polypharmacological therapeutic agent grounded in ethnopharmacological tradition. Addressing pharmacokinetic limitations and validating its efficacy and safety through rigorous preclinical and clinical studies are essential for its further development.

Research Insights

    Back to top